The Role of CDX2 in Intestinal Metaplasia Evaluated Using Immunohistochemistry
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Intestinal metaplasia (IM) has been regarded as a premalignant condition. This study evaluated the role of the transforming factor CDX2 according to the severity and type of IM. Methods: This analysis was performed on 383 subjects with IM in the antrum and/or body, with diagnoses that were categorized as controls, dysplasias, and gastric cancers. The IM grades were classifi ed into four groups as negative, mild, moderate or severe using the updated Sydney scoring system. The IM subtypes were categorized as type I, type II, and type III using high iron diamine and alcian blue (pH 2.5) staining. The CDX2 expression in the IM foci was evaluated using immunohistochemistry in specimens from the antrum and/or body. Results: CDX2 expression increased according to IM severity (p=0.001) but was not associated with the IM subtype (p=0.881) in the antrum specimens. Similarly, CDX2 expression increased according to the IM grade (p=0.001) but was not associated with the IM subtype (p=0.755) in the body specimens. CDX2 expression was also increased according to baseline disease in the antrum,especially dysplastic and GC group (p=0.003), but not in the body (p=0.582). However, status of Helicobacter pylori infection was not associated with CDX2 expression in the antrum (p=0.692) and body (p=0.271). Conclusions: These results show that CDX2 expression is associated with the IM grade regardless of the IM subtype and that it was more frequent in the dysplasia group. These results suggest that CDX2 expression might play an important role in the progression of IM in various environments that can affect neoplastic change.
Abstract
Background/Aims: Intestinal metaplasia (IM) has been regarded as a premalignant condition. This study evaluated the role of the transforming factor CDX2 according to the severity and type of IM. Methods: This analysis was performed on 383 subjects with IM in the antrum and/or body, with diagnoses that were categorized as controls, dysplasias, and gastric cancers. The IM grades were classifi ed into four groups as negative, mild, moderate or severe using the updated Sydney scoring system. The IM subtypes were categorized as type I, type II, and type III using high iron diamine and alcian blue (pH 2.5) staining. The CDX2 expression in the IM foci was evaluated using immunohistochemistry in specimens from the antrum and/or body. Results: CDX2 expression increased according to IM severity (p=0.001) but was not associated with the IM subtype (p=0.881) in the antrum specimens. Similarly, CDX2 expression increased according to the IM grade (p=0.001) but was not associated with the IM subtype (p=0.755) in the body specimens. CDX2 expression was also increased according to baseline disease in the antrum,especially dysplastic and GC group (p=0.003), but not in the body (p=0.582). However, status of Helicobacter pylori infection was not associated with CDX2 expression in the antrum (p=0.692) and body (p=0.271). Conclusions: These results show that CDX2 expression is associated with the IM grade regardless of the IM subtype and that it was more frequent in the dysplasia group. These results suggest that CDX2 expression might play an important role in the progression of IM in various environments that can affect neoplastic change.
참고문헌 (35)
- Correa P, "Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention", Cancer Res, 52, pp.6735~6740 (1992)
- Asaka M, "Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study", Helicobacter, 6, pp.294~299 (2001)
- Sonnenberg A, "A national study of Helicobactor pylori infection in gastric biopsy specimens", Gastroenterology, 139, pp.1894~1901 (2010)
- Yee YK, "Prevalence and time trend of intestinal metaplasia in Hong Kong", J Gastroenterol Hepatol, 24, pp.896~899 (2009)
- Wang J, "Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a metaanalysis", Digestion, 83, pp.253~260 (2011)
- Jass JR, "A variant of intestinal metaplasia associated with gastric carcinoma: a histochemical study", Histopathology, 3, pp.191~199 (1979)
- Filipe MI, "Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia", Int J Cancer, 57, pp.324~329 (1994)
- 이혜승, "Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 24, pp.140~148, Blackwell Publishing
- Inada K, "Gastric and intestinal mixed and solely intestinal types of intestinal metaplasia in the human stomach", Pathol Int, 47, pp.831~841 (1997)
- El-Zimaity HM, "Gastric intestinal metaplasia: subtypes and natural history", J Clin Pathol, 54, pp.679~683 (2001)
- Tava F, "Type or extension of intestinal metaplasia and immature", atypical “indefinite-fordysplasia” lesions as predictors of gastric neoplasia, 2006, pp.37, 1489~1497
- Grainger S, "Cdx2 regulates patterning of the intestinal epithelium", Dev Biol, 339, pp.155~165 (2010)
- Lord RV, "Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett’s esophagus and Barrett’s-associated adenocarcinoma", Surgery, 138, pp.924~931 (2005)
- Wu XS, "Expression of homeodomain protein CDX2 in gallbladder carcinomas", J Cancer Res Clin Oncol, 131, pp.271~278 (2005)
- Mutoh H, "Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice", Cancer Res, 64, pp.7740~7747 (2004)
- 강정묵, "CDX1 and CDX2 Expression in Intestinal Metaplasia, Dysplasia and Gastric Cancer", Journal of Korean Medical Science, 26(5), pp.647~653 (2011), 대한의학회
- Kim SY, "Serodiagnosis of Helicobacter pylori infection in Korean patients using enzyme-linked immunosorbent assay", J Immunoassay, 19, pp.251~270 (1998)
- Bodger K, "Detection of sulfated glycoproteins in intestinal metaplasia: a comparison of traditional mucin staining with immunohistochemistry for the sulfo-Lewis(a) carbohydrate epitope", J Clin Pathol, 56, pp.703~708 (2003)
- Mizoshita T, "Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis", J Cancer Res Clin Oncol, 129, pp.727~734 (2003)
- Gutiérrez-González L, "Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration", Dig Liver Dis, 40, pp.510~522 (2008)
- Mutoh H, "Transgenic Cdx2 induces endogenous Cdx1 in intestinal metaplasia of Cdx2-transgenic mouse stomach", FEBS J, 276, pp.5821~5831 (2009)
- Ahn SY, "Endoscopic diagnosis of opentype atrophic gastritis is related to the histological diagnosis of intestinal metaplasia and Cdx2 expression", Dig Dis Sci, 56, pp.1119~1126 (2011)
- Bai YQ, "Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach", Cancer Lett, 176, pp.47~55 (2002)
- Kim HS, "CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions", J Gastroenterol Hepatol, 21, pp.438~442 (2006)
- Hayes S, "Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence", J Clin Pathol, 64, pp.110~113 (2011)
- Park do Y, "CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance", Mod Pathol, 23, pp.54~61 (2010)
- Barros R, "CDX2 autoregulation in human intestinal metaplasia of the stomach: impact on the stability of the phenotype", Gut, 60, pp.290~298 (2011)
- Satoh K, "Aberrant expression of CDX2 in the gastric mucosa with and without intestinal metaplasia: effect of eradication of Helicobacter pylori", Helicobacter, 7, pp.192~198 (2002)
- Shiotani A, "Re-expression of sonic hedgehog and reduction of CDX2 after Helicobacter pylori eradication prior to incomplete intestinal metaplasia", Int J Cancer, 121, pp.1182~1189 (2007)
- Vauhkonen M, "Helicobacter pylori infection induces a reversible expression of the CDX2 transcription factor protein in human gastric epithelium", Scand J Gastroenterol, 43, pp.915~921 (2008)
- Xu Y, "Bile acids induce cdx2 expression through the farnesoid x receptor in gastric epithelial cells", J Clin Biochem Nutr, 46, pp.81~86 (2010)
- Kim JI, "Changing prevalence of upper gastrointestinal disease in 28 893 Koreans from 1995 to 2005", Eur J Gastroenterol Hepatol, 21, pp.787~793 (2009)
- Cassaro M, "Topographic patterns of intestinal metaplasia and gastric cancer", Am J Gastroenterol, 95, pp.1431~1438 (2000)
- Kato I, "A prospective study of atrophic gastritis and stomach cancer risk", Jpn J Cancer Res, 83, pp.1137~1142 (1992)
- Stemmermann GN, "Intestinal metaplasia of the gastric mucosa: a gross and microscopic study of its distribution in various disease states", J Natl Cancer Inst, 41, pp.627~634 (1968)